Medical Aspects of Chemical Warfare (2008) - The Black Vault

Medical Diagnostics63. EQM Research, Inc. Test-mate ChE Cholinesterase Test System. Web site. Available at http://www.eqmresearch.com/.Accessed January 19, 2007.64. Taylor PW, Lukey BJ, Clark CR, Lee RB, Roussel RR. Field verification of Test-mate ChE. Mil Med. 2003;168:314–319.65. Ellin RI, Burkhardt BH, Hart RD. A time-modified method for measuring red blood cell cholinesterase activity. ArchEnviron Health. 1973;27:48–49.66. Michel HO. An electrometric method for the determination of red blood cell and plasma cholinesterase activity. J LabClinical Med. 1949;34:1564–1568.67. US Department of Defense Cholinesterase Reference Laboratory. Standard operating procedure for the seventeen minutered blood cell acetylcholinesterase procedure. US Army Center for Health Promotion and Preventative Medicine: AberdeenProving Ground, Md; 2002. SOP CRL 40-2.7.68. US Department of Defense Cholinesterase Monitoring Program, Cholinesterase Reference Laboratory. Web site. Availableat http://chppm-www.apgea.army.mil/dls/CHOLIN.HTM. Accessed January 19, 2007.69. Dunn MA, Hackley BE, Sidell, FR. Pretreatment for nerve agent exposure. In: Sidell FR, Takafuji ET, Franz DR, eds.Medical Aspects of Chemical and Biological Warfare. In: Zajtchuk R, Bellamy RF, eds. The Textbooks of Military Medicine.Part I. Washington, DC: Department of the Army, Office of The Surgeon General, Borden Institute; 1997: 181–196.70. Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Rev. 1998;4:87–136.71. US Department of Health and Human Services. US Food and Drug Administration Web site. FDA approves pyridostigminebromide as pretreatment against nerve gas. FDA News. PO3-08, February 5, 2003. Available at http://www.fda.gov/bbs/topics/NEWS/2003/NEW00870.html. Accessed: January 19, 2007.72. Grunwald J, Raveh L, Doctor BP, Ashani Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity.Life Sci. 1994;54:991–997.73. Jiang H, Luo X, Bai D. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A:a drug of traditional medicine origin for the treatment of Alzheimer’s disease. Curr Med Chem. 2003;10:2231–2252.74. Lallement G, Baille V, Baubichon D, et al. Review of the value of huperzine as pretreatment of organophosphate poisoning.Neurotoxicology. 2002;23:1–5.75. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbalmedicine. Acta Pharmacol Sin. 2006;27:1–26.76. Raveh L, Grunwald J, Marcus D, Papier Y, Cohen, E, Ashani Y. Human butyrylcholinesterase as a general prophylacticantidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol. 1993;45:2465–2474.77. Yanagisawa N, Morita H, Nakajima T. Sarin experiences in Japan: acute toxicity and long-term effects. J Neurol Sci.2006;249:76–85.78. Papirmeister B, Feister AJ, Robinson SI, Ford RD. Medical Defense Against Mustard Gas: Toxic Mechanisms and PharmacologicalImplications, Boca Raton, Fla: CRC Press; 1991: 91–122.79. Black RM, Noort D. Methods for the retrospective detection of exposure to toxic scheduled chemicals. Part A: analysisof free metabolites. In: Mesilaakso M, ed. Chemical Weapons Convention Chemicals Analysis: Sample Collection, Preparation,and Analytical Methods. Chichester, West Sussex, England: John Wiley & Sons; 2005: 403–431.80. Noort D, Black RM. Methods for the retrospective detection of exposure to toxic scheduled chemicals. Part B: massspectrometric and immunochemical analysis of covalent adducts to proteins and DNA. In: Mesilaakso M, ed. ChemicalWeapons Convention Chemicals Analysis: Sample Collection, Preparation, and Analytical Methods. Chichester, West Sussex,England: John Wiley & Sons; 2005: 433–451.745